-
www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary19/colorectal-cancer-screening
May 18, 2021 - Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/WEqCV3NvnZAeLdC_pp6nVK
October 01, 2018 - Excludes persons living with HIV, transplant
recipients, and patients with renal failure.
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/vxPM4Bo9RXZGUDH6MWnDht
May 01, 2013 - A decision
analysis of long-term lithium treatment and the risk of renal failure.
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/oPmYxryXGu2occANaReagc
August 01, 2022 - household or close contacts of persons with
active tuberculosis without confirmed LTBI; and persons with renal
-
hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2015.jsp
January 01, 2015 - Comorbidity is not present, (1) Comorbidity is present
CM_RENLFAIL
AHRQ comorbidity measure: Renal
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ahrq-healthcare-horizon-scan-protocol-operations-manual-151001.pdf
September 01, 2015 - of the interventions is questionable at this time because of unexpected Phase 3 data (Symplicity
renal
-
effectivehealthcare.ahrq.gov/sites/default/files/ahrq-healthcare-horizon-scan-protocol-operations-manual-151001.pdf
September 01, 2015 - of the interventions is questionable at this time because of unexpected Phase 3 data (Symplicity
renal
-
hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2006.jsp
January 01, 2006 - measure: Pulmonary circulation disorders
CM_RENLFAIL
2002-2006
AHRQ comorbidity measure: Renal
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/patient-monitoring-systems-appendix-c.xlsx
January 01, 2024 - days) Vital signs data from CoNiM were found to associate with type of presenting complaint, level of renal
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/Z6Rfj-qwfoMbuLp-hBmhzS
May 01, 2021 - Renal sympathetic denervation in
patients with treatment-resistant hypertension (the
Symplicity HTN-2
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/Rm4E5SooP2GnqJ_HVRA5M4
January 01, 2017 - Renal sympathetic denervation in
patients with treatment-resistant hypertension
(the Symplicity HTN-2
-
cdsic.ahrq.gov/sites/default/files/2025-09/Quartz%20Assessment%20Report_To%20DTP_09.05.25.pdf
January 01, 2025 - Society of
Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal
-
hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2012.jsp
January 01, 2012 - Comorbidity is not present, (1) Comorbidity is present
CM_RENLFAIL
AHRQ comorbidity measure: Renal
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_disposition-comments.pdf
August 27, 2012 - No papers discussing end stage renal
disease or cystic fibrosis were eligible for
inclusion.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/antiplatelet-treatment_disposition-comments.pdf
September 25, 2013 - (e.g., patients with heart failure, obesity, diabetes, acute
coronary syndrome presentation, and renal
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotics-children-future_research.pdf
February 01, 2012 - is neuroleptic malignant syndrome (NMS), characterized by hyperthermia, rigidity,
rhabdomyolysis, renal
-
hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2013.jsp
January 01, 2013 - Comorbidity is not present, (1) Comorbidity is present
CM_RENLFAIL
AHRQ comorbidity measure: Renal
-
hcup-us.ahrq.gov/db/nation/kid/kid_2009_introduction.jsp
January 01, 2009 - : Pulmonary circulation disorders
CM_RENLFAIL
2003, 2006, 2009
AHRQ comorbidity measure: Renal
-
digital.ahrq.gov/sites/default/files/docs/citation/teahm_study_action_final061511comp.pdf
June 01, 2011 - Self-reported dialysis or renal failure
3. Cognitive impairment as evaluated by study staff
4.
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/k_QR3hvh2jVSPPLu6Q6m6r
November 13, 2022 - Asselbergs FW, Diercks GF, Hillege HL, et al;
Prevention of Renal and Vascular Endstage Disease
Intervention